The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Bispecific Antibodies for Solid Tumor Market Research Report 2025
Synopsis
Bispecific antibodies for solid tumors refer to a type of therapeutic antibody that is designed to recognize and bind two different targets on the surface of cancer cells. This approach is particularly relevant for solid tumors, which are often resistant to traditional single-target therapies. By having two different targets, bispecific antibodies are able to simultaneously engage both cancer cells and surrounding immune cells, triggering an immune response against the tumor. This dual-targeting approach can help to overcome some of the mechanisms that solid tumors use to evade immune detection, such as by downregulating expression of single target antigens or upregulating checkpoint regulators.Bispecific antibodies can also be designed to promote direct cell killing of cancer cells through recruitment and activation of immune cells, such as T-cells and Natural Killer (NK) cells. This mechanism of action can help to overcome resistance to cell death induced by single-target therapies.Recent advances in the development of bispecific antibodies have led to the availability of several FDA-approved molecules for the treatment of solid tumors, such as Catumaxomab for malignant ascites in ovarian cancer and Blinatumamab for certain types of leukemia. Many more bispecific antibodies are currently being evaluated in clinical trials for solid tumors, and are expected to have a significant impact on the treatment of cancer in the future.
The global Bispecific Antibodies for Solid Tumor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Bispecific Antibodies for Solid Tumor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Bispecific Antibodies for Solid Tumor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Bispecific Antibodies for Solid Tumor include Amgen, Genmab, Roche, BeiGene, Astellas Pharma, Johnson & Johnson, Akeso Biopharma and Abbvie, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Bispecific Antibodies for Solid Tumor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bispecific Antibodies for Solid Tumor.
Report Scope
The Bispecific Antibodies for Solid Tumor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bispecific Antibodies for Solid Tumor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bispecific Antibodies for Solid Tumor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
Genmab
Roche
BeiGene
Astellas Pharma
Johnson & Johnson
Akeso Biopharma
Abbvie
Segment by Type
Bispecific Antibodies without Fc
Bispecific Antibodies with Fc
Segment by Application
Cervical Cancer
Lung Cancer
Head and Neck Squamous Carcinoma
Stomach Cancer
Breast Cancer
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Bispecific Antibodies for Solid Tumor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Bispecific Antibodies for Solid Tumor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Bispecific antibodies for solid tumors refer to a type of therapeutic antibody that is designed to recognize and bind two different targets on the surface of cancer cells. This approach is particularly relevant for solid tumors, which are often resistant to traditional single-target therapies. By having two different targets, bispecific antibodies are able to simultaneously engage both cancer cells and surrounding immune cells, triggering an immune response against the tumor. This dual-targeting approach can help to overcome some of the mechanisms that solid tumors use to evade immune detection, such as by downregulating expression of single target antigens or upregulating checkpoint regulators.Bispecific antibodies can also be designed to promote direct cell killing of cancer cells through recruitment and activation of immune cells, such as T-cells and Natural Killer (NK) cells. This mechanism of action can help to overcome resistance to cell death induced by single-target therapies.Recent advances in the development of bispecific antibodies have led to the availability of several FDA-approved molecules for the treatment of solid tumors, such as Catumaxomab for malignant ascites in ovarian cancer and Blinatumamab for certain types of leukemia. Many more bispecific antibodies are currently being evaluated in clinical trials for solid tumors, and are expected to have a significant impact on the treatment of cancer in the future.
The global Bispecific Antibodies for Solid Tumor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Bispecific Antibodies for Solid Tumor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Bispecific Antibodies for Solid Tumor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Bispecific Antibodies for Solid Tumor include Amgen, Genmab, Roche, BeiGene, Astellas Pharma, Johnson & Johnson, Akeso Biopharma and Abbvie, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Bispecific Antibodies for Solid Tumor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bispecific Antibodies for Solid Tumor.
Report Scope
The Bispecific Antibodies for Solid Tumor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bispecific Antibodies for Solid Tumor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bispecific Antibodies for Solid Tumor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
Genmab
Roche
BeiGene
Astellas Pharma
Johnson & Johnson
Akeso Biopharma
Abbvie
Segment by Type
Bispecific Antibodies without Fc
Bispecific Antibodies with Fc
Segment by Application
Cervical Cancer
Lung Cancer
Head and Neck Squamous Carcinoma
Stomach Cancer
Breast Cancer
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Bispecific Antibodies for Solid Tumor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Bispecific Antibodies for Solid Tumor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Bispecific Antibodies for Solid Tumor Market Overview
1.1 Product Overview and Scope of Bispecific Antibodies for Solid Tumor
1.2 Bispecific Antibodies for Solid Tumor Segment by Type
1.2.1 Global Bispecific Antibodies for Solid Tumor Market Value Comparison by Type (2024-2030)
1.2.2 Bispecific Antibodies without Fc
1.2.3 Bispecific Antibodies with Fc
1.3 Bispecific Antibodies for Solid Tumor Segment by Application
1.3.1 Global Bispecific Antibodies for Solid Tumor Market Value by Application: (2024-2030)
1.3.2 Cervical Cancer
1.3.3 Lung Cancer
1.3.4 Head and Neck Squamous Carcinoma
1.3.5 Stomach Cancer
1.3.6 Breast Cancer
1.3.7 Others
1.4 Global Bispecific Antibodies for Solid Tumor Market Size Estimates and Forecasts
1.4.1 Global Bispecific Antibodies for Solid Tumor Revenue 2019-2030
1.4.2 Global Bispecific Antibodies for Solid Tumor Sales 2019-2030
1.4.3 Global Bispecific Antibodies for Solid Tumor Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Bispecific Antibodies for Solid Tumor Market Competition by Manufacturers
2.1 Global Bispecific Antibodies for Solid Tumor Sales Market Share by Manufacturers (2019-2024)
2.2 Global Bispecific Antibodies for Solid Tumor Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Bispecific Antibodies for Solid Tumor Average Price by Manufacturers (2019-2024)
2.4 Global Bispecific Antibodies for Solid Tumor Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Bispecific Antibodies for Solid Tumor, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Bispecific Antibodies for Solid Tumor, Product Type & Application
2.7 Bispecific Antibodies for Solid Tumor Market Competitive Situation and Trends
2.7.1 Bispecific Antibodies for Solid Tumor Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Bispecific Antibodies for Solid Tumor Players Market Share by Revenue
2.7.3 Global Bispecific Antibodies for Solid Tumor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Bispecific Antibodies for Solid Tumor Retrospective Market Scenario by Region
3.1 Global Bispecific Antibodies for Solid Tumor Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Bispecific Antibodies for Solid Tumor Global Bispecific Antibodies for Solid Tumor Sales by Region: 2019-2030
3.2.1 Global Bispecific Antibodies for Solid Tumor Sales by Region: 2019-2024
3.2.2 Global Bispecific Antibodies for Solid Tumor Sales by Region: 2025-2030
3.3 Global Bispecific Antibodies for Solid Tumor Global Bispecific Antibodies for Solid Tumor Revenue by Region: 2019-2030
3.3.1 Global Bispecific Antibodies for Solid Tumor Revenue by Region: 2019-2024
3.3.2 Global Bispecific Antibodies for Solid Tumor Revenue by Region: 2025-2030
3.4 North America Bispecific Antibodies for Solid Tumor Market Facts & Figures by Country
3.4.1 North America Bispecific Antibodies for Solid Tumor Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Bispecific Antibodies for Solid Tumor Sales by Country (2019-2030)
3.4.3 North America Bispecific Antibodies for Solid Tumor Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Bispecific Antibodies for Solid Tumor Market Facts & Figures by Country
3.5.1 Europe Bispecific Antibodies for Solid Tumor Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Bispecific Antibodies for Solid Tumor Sales by Country (2019-2030)
3.5.3 Europe Bispecific Antibodies for Solid Tumor Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Netherlands
3.6 Asia Pacific Bispecific Antibodies for Solid Tumor Market Facts & Figures by Country
3.6.1 Asia Pacific Bispecific Antibodies for Solid Tumor Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Bispecific Antibodies for Solid Tumor Sales by Country (2019-2030)
3.6.3 Asia Pacific Bispecific Antibodies for Solid Tumor Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Southeast Asia
3.6.9 China Taiwan
3.6.10 Australia
3.7 Latin America Bispecific Antibodies for Solid Tumor Market Facts & Figures by Country
3.7.1 Latin America Bispecific Antibodies for Solid Tumor Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Bispecific Antibodies for Solid Tumor Sales by Country (2019-2030)
3.7.3 Latin America Bispecific Antibodies for Solid Tumor Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Bispecific Antibodies for Solid Tumor Market Facts & Figures by Country
3.8.1 Middle East and Africa Bispecific Antibodies for Solid Tumor Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Bispecific Antibodies for Solid Tumor Sales by Country (2019-2030)
3.8.3 Middle East and Africa Bispecific Antibodies for Solid Tumor Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Bispecific Antibodies for Solid Tumor Sales by Type (2019-2030)
4.1.1 Global Bispecific Antibodies for Solid Tumor Sales by Type (2019-2024)
4.1.2 Global Bispecific Antibodies for Solid Tumor Sales by Type (2025-2030)
4.1.3 Global Bispecific Antibodies for Solid Tumor Sales Market Share by Type (2019-2030)
4.2 Global Bispecific Antibodies for Solid Tumor Revenue by Type (2019-2030)
4.2.1 Global Bispecific Antibodies for Solid Tumor Revenue by Type (2019-2024)
4.2.2 Global Bispecific Antibodies for Solid Tumor Revenue by Type (2025-2030)
4.2.3 Global Bispecific Antibodies for Solid Tumor Revenue Market Share by Type (2019-2030)
4.3 Global Bispecific Antibodies for Solid Tumor Price by Type (2019-2030)
5 Segment by Application
5.1 Global Bispecific Antibodies for Solid Tumor Sales by Application (2019-2030)
5.1.1 Global Bispecific Antibodies for Solid Tumor Sales by Application (2019-2024)
5.1.2 Global Bispecific Antibodies for Solid Tumor Sales by Application (2025-2030)
5.1.3 Global Bispecific Antibodies for Solid Tumor Sales Market Share by Application (2019-2030)
5.2 Global Bispecific Antibodies for Solid Tumor Revenue by Application (2019-2030)
5.2.1 Global Bispecific Antibodies for Solid Tumor Revenue by Application (2019-2024)
5.2.2 Global Bispecific Antibodies for Solid Tumor Revenue by Application (2025-2030)
5.2.3 Global Bispecific Antibodies for Solid Tumor Revenue Market Share by Application (2019-2030)
5.3 Global Bispecific Antibodies for Solid Tumor Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Corporation Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Bispecific Antibodies for Solid Tumor Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amgen Bispecific Antibodies for Solid Tumor Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Genmab
6.2.1 Genmab Corporation Information
6.2.2 Genmab Description and Business Overview
6.2.3 Genmab Bispecific Antibodies for Solid Tumor Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Genmab Bispecific Antibodies for Solid Tumor Product Portfolio
6.2.5 Genmab Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Bispecific Antibodies for Solid Tumor Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Roche Bispecific Antibodies for Solid Tumor Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 BeiGene
6.4.1 BeiGene Corporation Information
6.4.2 BeiGene Description and Business Overview
6.4.3 BeiGene Bispecific Antibodies for Solid Tumor Sales, Revenue and Gross Margin (2019-2024)
6.4.4 BeiGene Bispecific Antibodies for Solid Tumor Product Portfolio
6.4.5 BeiGene Recent Developments/Updates
6.5 Astellas Pharma
6.5.1 Astellas Pharma Corporation Information
6.5.2 Astellas Pharma Description and Business Overview
6.5.3 Astellas Pharma Bispecific Antibodies for Solid Tumor Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Astellas Pharma Bispecific Antibodies for Solid Tumor Product Portfolio
6.5.5 Astellas Pharma Recent Developments/Updates
6.6 Johnson & Johnson
6.6.1 Johnson & Johnson Corporation Information
6.6.2 Johnson & Johnson Description and Business Overview
6.6.3 Johnson & Johnson Bispecific Antibodies for Solid Tumor Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Johnson & Johnson Bispecific Antibodies for Solid Tumor Product Portfolio
6.6.5 Johnson & Johnson Recent Developments/Updates
6.7 Akeso Biopharma
6.6.1 Akeso Biopharma Corporation Information
6.6.2 Akeso Biopharma Description and Business Overview
6.6.3 Akeso Biopharma Bispecific Antibodies for Solid Tumor Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Akeso Biopharma Bispecific Antibodies for Solid Tumor Product Portfolio
6.7.5 Akeso Biopharma Recent Developments/Updates
6.8 Abbvie
6.8.1 Abbvie Corporation Information
6.8.2 Abbvie Description and Business Overview
6.8.3 Abbvie Bispecific Antibodies for Solid Tumor Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Abbvie Bispecific Antibodies for Solid Tumor Product Portfolio
6.8.5 Abbvie Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bispecific Antibodies for Solid Tumor Industry Chain Analysis
7.2 Bispecific Antibodies for Solid Tumor Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bispecific Antibodies for Solid Tumor Production Mode & Process
7.4 Bispecific Antibodies for Solid Tumor Sales and Marketing
7.4.1 Bispecific Antibodies for Solid Tumor Sales Channels
7.4.2 Bispecific Antibodies for Solid Tumor Distributors
7.5 Bispecific Antibodies for Solid Tumor Customers
8 Bispecific Antibodies for Solid Tumor Market Dynamics
8.1 Bispecific Antibodies for Solid Tumor Industry Trends
8.2 Bispecific Antibodies for Solid Tumor Market Drivers
8.3 Bispecific Antibodies for Solid Tumor Market Challenges
8.4 Bispecific Antibodies for Solid Tumor Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
